Microba Life Sciences (ASX:MAP) Gross-Profit-to-Asset % : 5.00% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Microba Life Sciences Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Microba Life Sciences's annualized Gross Profit for the quarter that ended in Dec. 2023 was A$2.80 Mil. Microba Life Sciences's average Total Assets over the quarter that ended in Dec. 2023 was A$56.09 Mil. Therefore, Microba Life Sciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 5.00%.

Microba Life Sciences Gross-Profit-to-Asset % Historical Data

The historical data trend for Microba Life Sciences's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microba Life Sciences Gross-Profit-to-Asset % Chart

Microba Life Sciences Annual Data

Trend

Jun22

Jun23

Gross-Profit-to-Asset %

5.99

6.20

Microba Life Sciences Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	-	-	9.44	2.14	5.00

Competitive Comparison of Microba Life Sciences's Gross-Profit-to-Asset %

For the Diagnostics & Research subindustry, Microba Life Sciences's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Microba Life Sciences's Gross-Profit-to-Asset % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Microba Life Sciences's Gross-Profit-to-Asset % falls into.

Microba Life Sciences Gross-Profit-to-Asset % Calculation

Microba Life Sciences's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2023 )	/	( (Total Assets (A: Jun. 2022 )	+	Total Assets (A: Jun. 2023 ))	/ count )
	=	2.678	/	( (39.479	+	46.953)	/ 2 )
	=	2.678	/	43.216
	=	6.20 %

Microba Life Sciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	2.804	/	( (46.953	+	65.236)	/ 2 )
	=	2.804	/	56.0945
	=	5.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Microba Life Sciences Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Microba Life Sciences's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Microba Life Sciences (ASX:MAP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Microba Life Sciences Ltd (ASX:MAP) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000

Website

https://www.microba.com

Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome which includes delivering gut microbiome testing services globally to consumers, clinicians, and researchers. The company's segment includes Testing Services, and Research and Development.

Microba Life Sciences (ASX:MAP) Headlines

No Headlines